GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Omadacycline (Nuzyra)

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug4 sources available - open source summaries, references and comparisons

Nuzyra

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

NUZYRA: source applicability and renal evidence limits

Do not infer a CRRT schedule or interchangeable oral/IV loading. The RX mirror is not independent corroboration of the matched label.

Before applying: Review oral fasting and cation-separation instructions.

Evidence for this qualification

Selected-source comparison; independent clinician adjudication pending.

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (4)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

NUZYRA: selected primary-label renal guidance and limits

This source only - not a merged recommendation

What matters first

Product: Adult NUZYRA IV and oral products for their labeled infections; the usual route-specific loading and administration instructions remain necessary.

Renal action / finding
No renal adjustment, including ESRD receiving hemodialysis.
Evidence or dialysis limit
Do not infer a CRRT schedule or interchangeable oral/IV loading.
Monitoring / application
Review oral fasting and cation-separation instructions.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Product / population
Adult NUZYRA IV and oral products for their labeled infections; the usual route-specific loading and administration instructions remain necessary.
Renal measure
Qualitative renal categories, including ESRD on hemodialysis
Source revision
05/2026
Retrieved
2026-11-07 (not the revision date)
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Do not infer a CRRT schedule or interchangeable oral/IV loading.

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Section 8.7; oral administration context in section 2

No renal dose adjustment is warranted in mild, moderate or severe impairment, including ESRD receiving hemodialysis. This does not replace the indication- and route-specific loading regimen. Oral tablets require fasting and separation from dairy, antacids and multivitamins; confirm the full administration instructions. No CRRT regimen is established in the selected passages.

Source revision: 05/2026 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51591524-4703-44c6-8bde-dce3e6a463d1

Scope: Selected sections checked against the identified source; not a complete monograph or independent clinician approval. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

NUZYRA: selected primary-label renal guidance and limits

Source retrieved 2026-11-07 - confirm current applicability

Qualified no-adjustment instruction; review dialysis evidence limits

Read the source and its limits

NUZYRA: selected RX renal passage

Source retrieved 2026-11-07 - confirm current applicability

Qualified no-adjustment instruction; review dialysis evidence limits

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

NUZYRA: selected primary-label renal guidance and limits

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Do not infer a CRRT schedule or interchangeable oral/IV loading.

Dialysis evidence: Qualified no-adjustment instruction; review dialysis evidence limits

Adult NUZYRA IV and oral products for their labeled infections; the usual route-specific loading and administration instructions remain necessary.

Renal method: Qualitative renal categories, including ESRD on hemodialysis
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

NUZYRA: selected RX renal passage

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Do not infer a CRRT schedule or interchangeable oral/IV loading.

Dialysis evidence: Qualified no-adjustment instruction; review dialysis evidence limits

Adult NUZYRA IV and oral products for their labeled infections; the usual route-specific loading and administration instructions remain necessary.

Renal method: Qualitative renal categories, including ESRD on hemodialysis
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

NUZYRA: source applicability and renal evidence limits

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

NUZYRA: source applicability and renal evidence limits

Do not infer a CRRT schedule or interchangeable oral/IV loading. The RX mirror is not independent corroboration of the matched label.

How to use this: Review oral fasting and cation-separation instructions.

NUZYRA: selected primary-label renal guidance and limitsNUZYRA: selected RX renal passage

Selected-source comparison; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source

NUZYRA: selected primary-label renal guidance and limits

Adult NUZYRA IV and oral products for their labeled infections; the usual route-specific loading and administration instructions remain necessary.

Method: Qualitative renal categories, including ESRD on hemodialysis

Read this complete source summary
Rxlist source

NUZYRA: selected RX renal passage

Adult NUZYRA IV and oral products for their labeled infections; the usual route-specific loading and administration instructions remain necessary.

Method: Qualitative renal categories, including ESRD on hemodialysis

Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeNUZYRA - adult indication-specific loading and renal guidanceNUZYRA: selected primary-label renal guidance and limitsNUZYRA: selected RX renal passageUCSF - omadacycline
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51591524-4703-44c6-8bde-dce3e6a463d1

Product and population scope

Adult Omadacycline (Nuzyra). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-omadacycline · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

NUZYRA - adult indication-specific loading and renal guidance

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Source date: DailyMed updated 2026-05-27; prescribing information revised 2026-05
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adults: IV loading for CABP or ABSSSI is 200 mg over 60 minutes on day 1, or 100 mg over 30 minutes twice on day 1. Maintenance is 100 mg IV over 30 minutes daily or 300 mg orally daily, for 7-14 days.

Oral-only loading differs: CABP uses 300 mg twice on day 1; ABSSSI uses 450 mg daily on days 1 and 2. Do not exchange these loading schedules.

No adjustment is required for renal impairment, including hemodialysis, or hepatic impairment.

For oral doses, fast at least 4 hours beforehand; afterward avoid food/drinks except water for 2 hours, and dairy, antacids and multivitamins for 4 hours.

RDM30-092-omadacycline-1 · Source locator: NUZYRA - adult indication-specific loading and renal guidance; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51591524-4703-44c6-8bde-dce3e6a463d1
Retrieved
2026-09-05
DailyMed Set ID
51591524-4703-44c6-8bde-dce3e6a463d1
Renal-function method
No renal-function dose bands specified for this summary.
Source date/version
DailyMed updated 2026-05-27; prescribing information revised 2026-05
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
589cf7e806f56d8adb8da22bdef6d5919533f65246f12f9b66674d13e895a204
Official

NUZYRA: selected primary-label renal guidance and limits

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Adult NUZYRA IV and oral products for their labeled infections; the usual route-specific loading and administration instructions remain necessary.

Renal method: Qualitative renal categories, including ESRD on hemodialysis
Source date: 05/2026
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Do not infer a CRRT schedule or interchangeable oral/IV loading.

Dialysis evidence: Qualified no-adjustment instruction; review dialysis evidence limits

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Section 8.7; oral administration context in section 2

No renal dose adjustment is warranted in mild, moderate or severe impairment, including ESRD receiving hemodialysis. This does not replace the indication- and route-specific loading regimen. Oral tablets require fasting and separation from dairy, antacids and multivitamins; confirm the full administration instructions. No CRRT regimen is established in the selected passages.

RDM72-omadacycline-label-1 · Source locator: Section 8.7; oral administration context in section 2

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51591524-4703-44c6-8bde-dce3e6a463d1
Retrieved
2026-11-07
Renal-function method
Qualitative renal categories, including ESRD on hemodialysis
Source date/version
05/2026
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
eaaba33c8c69d0ab5244a5c85d64de6eaa9347d9b88059587ad944895514b257
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

NUZYRA: selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / label mirror · Adult NUZYRA IV and oral products for their labeled infections; the usual route-specific loading and administration instructions remain necessary.

Renal method: Qualitative renal categories, including ESRD on hemodialysis
Source date: Revision date not established in reviewed mirror passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Do not infer a CRRT schedule or interchangeable oral/IV loading.

Dialysis evidence: Qualified no-adjustment instruction; review dialysis evidence limits

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Section 8.7; oral administration context in section 2

The mirror explicitly reports no renal adjustment, including ESRD receiving hemodialysis. Oral and IV administration requirements remain product-specific; this is not independent corroboration of the label.

RDM72-omadacycline-rx-1 · Source locator: Section 8.7; oral administration context in section 2

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/nuzyra-drug/
Retrieved
2026-11-07
Renal-function method
Qualitative renal categories, including ESRD on hemodialysis
Source date/version
Revision date not established in reviewed mirror passage.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
40657e4a799b08889fbef32a624c42b8530f5bc3521eaf25ab41892a89e3fd66
Separate professional-source layer

University and professional protocols

Professional

UCSF - omadacycline

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

The institutional IV schedule is 200 mg once followed by 100 mg daily. The listed oral schedule is 450 mg daily for two doses followed by 300 mg daily. The source does not reduce these regimens for renal dysfunction or HD.

Oral administration requires at least 4 hours fasting before and 2 hours after a dose. Loading may be omitted for selected NTM regimens under specialist care. Indication-specific product labeling must be checked separately; the displayed oral loading schedule is not automatically appropriate to every labeled infection.

RDM30-051-omadacycline-1 · Source locator: UCSF - omadacycline; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/omadacycline
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
fe33210c3e984ab366036fcb848c1298b62d129677442df58610511d4099988e

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51591524-4703-44c6-8bde-dce3e6a463d1
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
dad2926125d43513529be355404e6b95e892dca09a28dcc63157b12f6e3541fe
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top